APP and amyloidosis: In our lab, we recently reported that in vivo administration of the p38α-specific inhibitor MW150 to APP/PS1 mice did not alter overall amyloid burden or colocalization of 6E10 and Iba1-positive microglia in the cortex, suggesting no effect on amyloid phagocytosis, though this manipulation did significantly increase the number of microglia residing in close proximity (<15 μm) to plaques (plaque-associated microglia) [23].